Results 111 to 120 of about 423,879 (287)

The first metatarsophalangeal joint in gout: a systematic review and meta analysis [PDF]

, 2016
Background: The aim of this review was to qualitatively synthesise studies that have investigated characteristics of the first metatarsophalangeal joint (1st MTP) in gout and to undertake a meta-analysis to estimate the average prevalence of acute 1st ...
Dalbeth, N, Rome, K, Stewart, S, Vandal, AC   +3 more
core   +2 more sources

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Critical appraisal of the role of pegloticase in the management of gout

Open Access Rheumatology: Research and Reviews, 2012
Hang-Korng Ea,1,2 Pascal Richette1,21Hôpital Lariboisière, Rheumatology Department, Paris, France; 2University of Paris Diderot, Sorbonne Paris Cité, Paris, FranceAbstract: Gout is a debilitating disease secondary to ...
Ea HK, Richette P
doaj  

Organic Electrochemical Transistors in Tissue‐Interfaced Bioelectronics

Advanced Science, Volume 13, Issue 6, 30 January 2026.
This article reviews the design, fabrication, and biological application of organic electrochemical transistors (OECTs), emphasizing their potential in tissue‐interfaced bioelectronics. It covers the fundamental principles of OECTs, strategies for enhancing tissue interfacing, and the development of skin‐mounted and implantable systems.
Ruixiang Bai, Zeyu Zhao, Feng Yan
wiley   +1 more source

Prophylaxis for acute gout flares after initiation of urate-lowering therapy [PDF]

Rheumatology, 2014
This review summarizes evidence relating to prophylaxis for gout flares after the initiation of urate-lowering therapy (ULT). We searched MEDLINE via PubMed for articles published in English from 1963 to 2013 using MEsH terms covering all aspects of prophylaxis for flares.
Augustin, Latourte, Thomas, Bardin, Pascal, Richette   +2 more
openaire   +2 more sources

Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients?:A Danish cohort study [PDF]

, 2015
INTRODUCTION: There is increasing evidence that both hyperuricemia and gout increase the risk of cardiovascular morbidity and mortality. Whether urate crystal precipitation confers a particular risk above what is already inherent in having hyperuricemia ...
Hallas, Jesper, Larsen, Kasper Søltoft, Lindegaard, Hanne Merete, Pottegård, Anton   +3 more
core   +2 more sources

Evaluation of ASC as a therapeutic target for Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract Neuroinflammation is increasingly recognized as a central contributor to the pathogenesis and progression of Alzheimer's disease (AD). The apoptosis‐associated speck‐like protein containing a CARD (ASC), encoded by the PYCARD gene, plays a critical role in the formation of multiple inflammasomes, including NLRP3, a key mediator of inflammation
W. Brent Clayton, Joshua A. Kulas, Jiahui Liu, Nidhi Walia, Claudia Rangel‐Barajas, Travis Johnson, Jie Zhang, Kun Huang, Andrew D. Mesecar, Jeffrey L. Dage, Bruce T. Lamb, Alan D. Palkowitz, Timothy I. Richardson   +12 more
wiley   +1 more source

Serendipitous Symptom Control: Allopurinol for Spasticity in a Case of SPG4‐Linked Hereditary Spastic Paraplegia—A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
Graphical representation of spasticity and medication changes. (A) Temporal course of lower limb spasticity measured by MAS scores. Following initiation of allopurinol 300 mg daily at baseline (red dashed line), there was a rapid and sustained improvement in spasticity from severe (MAS = 4) to mild (MAS = 1.8) over 12 months of follow‐up, represented ...
Ziad W. Elmezayen, Hossam Salameh, Asem Afana, Anwar Zahran   +3 more
wiley   +1 more source

Musculoskeletal ultrasonography in gout [PDF]

, 2015
Gout is a frequent inflammatory disease induced by the deposition of monosodium urate crystals in joints and extra-articular tissues. The natural history of the disease includes four different phases: asymptomatic hyperuricemia, acute attacks ...
Finucci, Annacarla, Iagnocco, Annamaria, Rutigliano, IOLANDA MARIA, Scirocco, Chiara   +3 more
core   +1 more source

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST):a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia [PDF]

, 2014
Introduction: Gout affects 2.5% of the UK's adult population and is now the most common type of inflammatory arthritis. The long-term management of gout requires reduction of serum urate levels and this is most often achieved with use of xanthine oxidase
Annemans, Burns, Committee, Evans, Feig, Hansson, Ioachimescu, Khanna, Kuo, Luk, Pal, Schumacher, Smith, Strasak, Strasak, Wortmann, Zhang   +16 more
core   +6 more sources